| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/26/2007 | WO2007000671A3 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
| 04/26/2007 | WO2006137931A3 Human monoclonal antibodies against hendra and nipah viruses |
| 04/26/2007 | WO2006133795A3 A new human t-cell lymphotropic virus (htlv-3): nucleic acid and peptidic sequences thereof and method for detecting htlv-3 |
| 04/26/2007 | WO2006121422A8 Antibodies against clostridium difficile toxins and uses thereof |
| 04/26/2007 | WO2006109191A3 Human anti-interferon gamma antibodies and methods of use thereof |
| 04/26/2007 | WO2006104615A3 Influenza nucleic acids, polypeptides, and uses thereof |
| 04/26/2007 | WO2006093923A3 Treatment of bone disorders |
| 04/26/2007 | WO2006089678A3 Antibodies and peptides binding to hiv tat, and uses thereof |
| 04/26/2007 | WO2006071896A3 Epitope-based sars vaccine |
| 04/26/2007 | WO2006059247A8 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC |
| 04/26/2007 | WO2006011151A8 Vaccine comprising recombinant ct or lt toxin |
| 04/26/2007 | US20070093441 useful to efficiently induce self-specific immune responses; comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin |
| 04/26/2007 | US20070093434 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| 04/26/2007 | US20070092918 Detection of the PC-LECTIN protein which correlates to the presence of an androgen-dependent prostate cancer cell; drug target and diagnostic marker for prostate cancer |
| 04/26/2007 | US20070092538 Immunogenic reagents from west nile virus |
| 04/26/2007 | US20070092537 Compositions and methods for the treatment of canine influenza virus disease |
| 04/26/2007 | US20070092536 Cold-adapted equine influenza viruses |
| 04/26/2007 | US20070092535 Delivery of drugs to mucosal surfaces |
| 04/26/2007 | US20070092534 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| 04/26/2007 | US20070092533 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus |
| 04/26/2007 | US20070092532 Arthritis vaccines and methods |
| 04/26/2007 | US20070092531 Compositions for Immunotherapy and Uses Thereof |
| 04/26/2007 | US20070092530 Antibodies as T cell receptor mimics, methods of production and uses thereof |
| 04/26/2007 | US20070092529 Using gene encoding transmembrane ptorein |
| 04/26/2007 | US20070092528 Superantigen fusion protein for anti-cancer therapy and methods for the production thereof |
| 04/26/2007 | US20070092527 Proton-sensing g-protein coupled receptors and dna sequences thereof |
| 04/26/2007 | US20070092526 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
| 04/26/2007 | US20070092525 Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
| 04/26/2007 | US20070092524 Method for the treatment and prophylaxis of avian influenza infection |
| 04/26/2007 | US20070092523 Combination Therapy Of Respiratory Diseases Using Antibodies |
| 04/26/2007 | US20070092522 Contacting a monoclonal antibody with a soluble antigen; cancer vaccines |
| 04/26/2007 | US20070092521 producing a glycosylated monoclonal antibody or Fc fusion protein by culturing the cell in the presence of kifunensine ; for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases |
| 04/26/2007 | US20070092520 Humanized Anti-CMET Antagonists |
| 04/26/2007 | US20070092519 Method for diagnosing chronic myeloid leukemia |
| 04/26/2007 | US20070092518 Anti-TNFalpha antibodies and methods of use |
| 04/26/2007 | US20070092517 Truncated memapsin 2 compositions and treatments |
| 04/26/2007 | US20070092516 Antibody preparation |
| 04/26/2007 | US20070092515 Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin |
| 04/26/2007 | US20070092514 Novel secreted immunomodulatory proteins and uses thereof |
| 04/26/2007 | US20070092513 Antiproliferative agents; anticancer agents; controlling excessive proliferation or migration of smooth muscle cells by treating said smooth muscle cells with an effective amount of an antagonist of a native ErbB4 receptor |
| 04/26/2007 | US20070092512 Preventing bacterial or viral infectivity and composition containing infection preventing additive |
| 04/26/2007 | US20070092511 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| 04/26/2007 | US20070092510 Gene expression inhibition; drug screening; reduction of nociception; modulation of the activity and/or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter |
| 04/26/2007 | US20070092508 Detoxification depot for Alzheimer's disease |
| 04/26/2007 | US20070092507 Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| 04/26/2007 | US20070092506 Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
| 04/26/2007 | US20070092505 Production of humanized antibodies in transgenic animals |
| 04/26/2007 | US20070092504 Use of agents that modulate the interaction between PD-1 and its ligands in the downmodulation of immune responses |
| 04/26/2007 | US20070092498 Methods of diagnosing, prognosing and treating breast cancer |
| 04/26/2007 | US20070092444 Inhibition of inward sodium currents in cancer |
| 04/26/2007 | US20070092443 Antibodies That Recognize Hyperproliferative Cells and Methods of Making and Using Same |
| 04/26/2007 | CA2638899A1 Tumor-targeted nanodelivery systems to improve early mri detection of cancer |
| 04/26/2007 | CA2630415A1 Fc labeling for immunostaining and immunotargeting |
| 04/26/2007 | CA2626688A1 Agents for treating cardiopathy |
| 04/26/2007 | CA2626556A1 Antibody-based therapeutics with enhanced adcc activity |
| 04/26/2007 | CA2626542A1 Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
| 04/26/2007 | CA2626489A1 Influenza viruses able to infect canids, uses thereof |
| 04/26/2007 | CA2626452A1 Canine influenza virus and related compositions and methods of use |
| 04/26/2007 | CA2626257A1 Multiclade hiv vaccines |
| 04/26/2007 | CA2626253A1 Mucosal and systemic immunizations with alphavirus replicon particles |
| 04/26/2007 | CA2625992A1 Inhibition of placenta growth factor (p1gf) mediated metastasis and/or angiogenesis |
| 04/26/2007 | CA2625812A1 Reduction and prevention of cell-associated hiv transepithelial migration, microbides and other formulations and methods |
| 04/26/2007 | CA2625664A1 Human antibodies against il13 and therapeutic uses |
| 04/26/2007 | CA2625580A1 Targeted biocides |
| 04/26/2007 | CA2625406A1 Functional influenza virus like particles (vlps) |
| 04/26/2007 | CA2624931A1 Therapeutic agent |
| 04/26/2007 | CA2624894A1 Anti-glypican-3 antibody |
| 04/26/2007 | CA2624648A1 Methods of decreasing vascular calcification using il-1 inhibitors |
| 04/26/2007 | CA2624617A1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 04/26/2007 | CA2607056A1 Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| 04/26/2007 | CA2592065A1 Glp-1 agonists, compositions, methods and uses |
| 04/25/2007 | EP1777293A1 Transferrin receptor genes of Moraxella |
| 04/25/2007 | EP1777236A1 Modified saccharides having improved stability in water |
| 04/25/2007 | EP1777235A1 Compositions and methods for treating inflammatory disorders |
| 04/25/2007 | EP1777233A2 Gonococcal proteins and nucleic acids |
| 04/25/2007 | EP1776963A1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 04/25/2007 | EP1776962A1 Vaccine |
| 04/25/2007 | EP1776961A1 Immunizing against HIV infection |
| 04/25/2007 | EP1776583A2 Methods for preparing t-cells for cell therapy |
| 04/25/2007 | EP1776456A2 Isolated chimeric proteins of modified lumazine synthase |
| 04/25/2007 | EP1776387A1 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| 04/25/2007 | EP1776386A1 Anti-ghrelin antibodies |
| 04/25/2007 | EP1776384A2 Variant fc regions |
| 04/25/2007 | EP1776141A2 Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| 04/25/2007 | EP1776136A2 Treatment of conditions involving demyelination |
| 04/25/2007 | EP1776132A2 Natriuretic compounds, conjugates, and uses thereof |
| 04/25/2007 | EP1476463B1 Mhc class i peptide epitopes from the human 5t4 tumor-associated antigen |
| 04/25/2007 | EP1425042B1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 04/25/2007 | EP1320542B1 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof |
| 04/25/2007 | EP1259813B1 Diagnosis of malignant neoplasms |
| 04/25/2007 | EP1255554B1 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250 |
| 04/25/2007 | EP1253938B1 Immunization against carcinoma and the preliminary stages thereof |
| 04/25/2007 | EP1223964B1 April receptor (bcma) and uses thereof |
| 04/25/2007 | EP1210425B1 Baff receptor (bcma), an immunoregulatory agent |
| 04/25/2007 | EP1135025B1 Plasmid maintenance system for antigen delivery |
| 04/25/2007 | EP0984023B1 Cell surface molecule mediating cell adhesion and signal transmission |
| 04/25/2007 | EP0964925B1 A basal cell carcinoma tumor suppressor gene |
| 04/25/2007 | EP0960887B1 T cell epitope peptides |
| 04/25/2007 | EP0934077B1 Polyanionic polymers as adjuvants for mucosal immunization |
| 04/25/2007 | EP0901526B1 Cortistatin: neuropeptides, compositions and methods |